- Home
- BRNS vs MYO Comparison
BRNS vs MYO Comparison
Compare BRNS & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- MYO
- Stock Information
- Founded
- BRNS 2016
- MYO 2004
- Country
- BRNS United Kingdom
- MYO United States
- Employees
- BRNS N/A
- MYO N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- MYO Industrial Specialties
- Sector
- BRNS Health Care
- MYO Health Care
- Exchange
- BRNS Nasdaq
- MYO Nasdaq
- Market Cap
- BRNS 48.3M
- MYO 44.6M
- IPO Year
- BRNS 2021
- MYO 2017
- Fundamental
- Price
- BRNS $1.07
- MYO $0.83
- Analyst Decision
- BRNS Strong Buy
- MYO Strong Buy
- Analyst Count
- BRNS 1
- MYO 3
- Target Price
- BRNS $3.00
- MYO $8.17
- AVG Volume (30 Days)
- BRNS 42.9K
- MYO 1.5M
- Earning Date
- BRNS 11-05-2025
- MYO 11-05-2025
- Dividend Yield
- BRNS N/A
- MYO N/A
- EPS Growth
- BRNS N/A
- MYO N/A
- EPS
- BRNS N/A
- MYO N/A
- Revenue
- BRNS $14,969,000.00
- MYO $40,760,091.00
- Revenue This Year
- BRNS N/A
- MYO $25.69
- Revenue Next Year
- BRNS N/A
- MYO $23.52
- P/E Ratio
- BRNS N/A
- MYO N/A
- Revenue Growth
- BRNS 1766.46
- MYO 93.08
- 52 Week Low
- BRNS $0.64
- MYO $0.80
- 52 Week High
- BRNS $2.92
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- BRNS 41.80
- MYO 25.54
- Support Level
- BRNS $1.08
- MYO $0.80
- Resistance Level
- BRNS $1.20
- MYO $1.01
- Average True Range (ATR)
- BRNS 0.10
- MYO 0.07
- MACD
- BRNS -0.01
- MYO 0.02
- Stochastic Oscillator
- BRNS 22.16
- MYO 9.20
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).